RBx 10558
Alternative Names: PPD-10558; RBx-10558Latest Information Update: 07 Sep 2014
At a glance
- Originator Ranbaxy Laboratories
- Developer Furiex Pharmaceuticals
- Class Antihyperlipidaemics
- Mechanism of Action HMG-CoA reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hypercholesterolaemia
Most Recent Events
- 08 Dec 2011 Discontinued - Phase-II for Hypercholesterolaemia in USA (PO)
- 23 Mar 2011 Phase-IIb clinical trials in Hypercholesterolaemia (with history of statin-associated myalgia) in USA (PO)
- 20 Oct 2008 Ranbaxy Laboratories has been acquired by Daiichi Sankyo